| abstract |
The invention relates to the use of a pharmaceutical preparation, containing a trifunctional bispecific and/or trispecific antibody with the following properties: a) binding to a T-cell; b) binding to at least one antigen on a tumour cell, connected to malignant ascites and/or a pleural effusion; c) binding by means of the Fc component thereof (for bispecific antibodies), or by means of a third specificity (for trispecific antibodies) to Fc-receptor-positive cells to destroy the tumour cells in treatment of malignant ascites and/or a pleural effusion. |